A B S T R A C T The kinetics of distribution of 3,3',5-triiodo-L-thyronine (T3) have been studied employing both a single-injection and a continuous infusion of T3-"'J. External monitoring of radioactivity in the liver during the infusion permitted estimation of the hepatic distribution volume (VH) and the one-way hepatic clearance (CH) of the hormone. Among 10 euthyroid control subjects, V. averaged 2.07 liters ±0.50 (SD), and the mean value for CH, 231 ml of plasma per min (±64). In three euthyroid men whose plasma showed decreased binding capacity by thyroxine-binding globulin (TBG) abnormally high VH and CH values were found, the increase in CH being proportional to the decrease in binding activity by plasma proteins. Among all 13 subjects, there was a high correlation (+ 0.86) between CH and the proportion of free hormone in plasma, measured in vitro.
A B S T R A C T The kinetics of distribution of 3,3',5-triiodo-L-thyronine (T3) have been studied employing both a single-injection and a continuous infusion of T3-"'J. External monitoring of radioactivity in the liver during the infusion permitted estimation of the hepatic distribution volume (VH) and the one-way hepatic clearance (CH) of the hormone. Among 10 euthyroid control subjects, V. averaged 2.07 liters ±0.50 (SD) , and the mean value for CH, 231 ml of plasma per min (±64). In three euthyroid men whose plasma showed decreased binding capacity by thyroxine-binding globulin (TBG) abnormally high VH and CH values were found, the increase in CH being proportional to the decrease in binding activity by plasma proteins. Among all 13 subjects, there was a high correlation (+ 0.86) between CH and the proportion of free hormone in plasma, measured in vitro.
In four patients with hyperthyroid Graves' disease VH ranged from 3.2 to 4.2 liters and Ci was elevated in every case, averaging 989 ml/min. The increase in CH in this group was out of proportion to the elevation of free hormone fraction in plasma. Seven patients who were either euthyroid or hypothyroid after treatment of Graves' disease showed a slight but significant increase in CH compared with the euthyroid controls without Graves' disease. The percentage of free hormone in the plasma of the treated group was normal or low and therefore could not explain the persistent elevation in unidirectional hepatic clearance observed.
The rate of accumulation of labeled T3 in the tissues of the thigh during the interval from Received for publication 20 November 1969 and in revised form 22 January 1970. sustaining infusion of tracer was slow compared to the rate of equilibration in the liver and did not differ significantly among the various groups studied. These latter findings suggest that in slowly equilibrating tissues such as the thigh the kinetics of Ts distribution are relatively insensitive to alterations in hormonebinding activity by plasma proteins.
INTRODUCTION
There is accumulating evidence that 3,3',5-triiodo-L-thyronine (T3) plays a more important role in a quantitative sense than is relatively low concentration in blood would suggest (1, 2) . Although published estimates of total distribution volume vary widely (3) (4) (5) (6) (7) , the reported values suggest that more than nine-tenths of the extrathyroidal pool of T3 lies outside the vascular compartment. However, quantitative data in the human are lacking in regard to the rates of transfer of Ta b2-tween plasma and tissue and the distribution of the hormone in extravascular sites. The rapidity with which labeled Ts leaves the blood after a single injection of the tracer makes analysis of kinetics data difficult. In order to overcome this problem we have employed a method involving a continuous infusion of labeled Ts. During the period when the plasma concentration of tracer is maintained at a constant level, monitoring of radioactivity in various sites, such as the liver, provides a means of estimating the rate of penetration of hormone into tissues. This report describes the method and presents the results obtained in euthyroid subjects with either normal or decreased plasma TBG rapidly at time zero, followed immediately by an infusion at decreasing rates. The concentration of TCA-insoluble 'I in plasma is shown by squares, radioactivity over the liver by triangles, and radioactivity over the thigh by solid circles.
formulae:
Where Do is the priming dose, in milliliters, and k1 is the slope of the plasma-time curve (single-injection data) during any interval i. For example, k2 is given by (log C2 -log C1) / t2 -ti, where C1 and C2 are the plasma concentration at time ti and t2, respectively, after the single injection. This formuk3 lation is an extension of one developed previously to calculate the infusion rate of labeled glucose in an assumed singlecompartment system (8) . The objective is to achieve a constant level of tracer in the plasma extending from the ini-CM.
tial priming dose throughout the period of infusion. The continuous infusion experiments were begun on the 3rd or 4th day after the single injection. The patient was recumbent for at least 30 min before and during the period of the infusion. A sample of blood was collected for determination of the residual radioactivity in the plasma. A priming dose, exactly 3.0 ml of a solution containing approximately 15 1ACi of TAX'I in dilute albumin, was rapidly injected intravenously and followed immediately by an infusion of additional solution containing the same concentration of tracer. The infusion rates were controlled within 5% of the calculated rates by means of a Harvard pump (Harvard Apt4 paratus Co., Dover, Mass.). In most of the subjects studied, the infusion was continued for 120 min; in some cases, the 100 120 infusion was terminated after 90 min. The volume infused during the entire period of the study ranged from 9 to 12 ml, including the priming dose. Samples were collected from a le plasma con-vein in the opposite arm at 3, 6, and 10 min after injection of le injection of the priming dose, and at 10-to 20-min intervals thereafter plasma concen-until the end of the infusion. Plasma was assayed for TCAfour straight precipitable 'LI. The exact position of the hepatic detector was determined during the single-injection study as the point giving the maximum counting rate at 10 min after injection. The instrumentation used and the method of calibrating the hepatic detector have been described (9) . Scintiscans of the abdomen were made in several cases at the end of the infusion of TA-'I and in other cases within 30 min after the single injection of the label. In every scan, the highest concentration of 'I was in the liver, which showed a uniform pattern of distribution. The kidneys were visualized in posterior views taken as early as 30 min after injection of TA-I, but the apparent renal concentration of label was lower than that in the liver.
Hepatic distribution volume (VH) (See Fig. 2 ). The following expression was used:
Where VH is the hepatic distribution volume for T3 at equilibrium, in liters, Lm.. is the maximum counting rate over the liver (at distribution-equilibrium), Lo is the counting rate over the liver at time zero, determined by extrapolation of the intial portion of the heaptic uptake curve; C"'eq) is the concentration of 'I in plasma at equilibrium, in microcuries per liter; and F is a calibration factor relating counts per minute observed over the liver to microcuries contained within the liver. (See reference 9 for detailed description of the method of calibration.)
The t = 0 correction (Lo), although variable from one subject to another, averaged 40%o of Lma.. This correction represents circulating radioactivity both within the liver and in extrahepatic tissues within view of the detector.
(See Appendix for a discussion of the validity of this correction.)
Unidirectional hepatic clearance (CH). Points on the time-curve of hepatic radioactivity, Lt, were subtracted from The resulting data, Lmax-Lt, when plotted against time on semi-logarithmic coordinates, fit a single exponential function for at least two half-times. The slope, X, of the derived exponential function was used to calculate one-way hepatic clearance, CH, from the formula: CH = VH X -1000, were CH is in milliliters per minute, VH is in liters, and X is in minutes'.
Extrahepatic distribution (VeH). The apparent volume of distribution of the equilibrating tracer increases with time after the single injection of Ts3ruI. The distribution volume outside the vascular (plasma) compartment, VEv, at any time, t, was calculated from the expression: VEYv(t) = 100/Cp(t) -VP, where Cp(t) is the concentration of 'I (TCA-insoluble) in plasma at time t, expressed in per cent of administered dose per liter, and VP is the plasma volume, in liters. It is assumed that equilibration in the liver is completed within 20 min after the single dose of Ts-'31I. This permits calculation of the apparent volume of distribution in extrahepatic tissues (VEH) at any time t beyond 20 min after injection:
Subjects. As control subjects, 10 male adults were studied. All were patients who had chronic, nondebilitating disease, were euthyroid, gave no history of thyroid disease, and were receiving no drugs known to affect plasma binding of thyroid hormones. Serum total T4 and free T4 concentration were normal in every case. All had normal hepatic function by clinical and routine laboratory evaluation.
Four patients with moderately severe hyperthyroidism (diffuse toxic goiter) were studied. All had mild exophthalmos, and one also had pretibial myxedema (subject P.B.). Subject W.P. had been begun on antithyroid medication, methimazole, 10 mg every 8 hr, 10 days previously, but he was still clinically thyrotoxic at the time of the study. Time (Minutes) FIGURE 3 The time-course of hepatic radioactivity during the infusion of TA-'I in three control subjects and in one hyperthyroid patient (J. P.). The points depicting hepatic radioactivity, Lt (triangles), have been normalized to the maximum value, Lmax, reached during the infusion. The derived values, Lmax -Lt (solid circles), fit a single exponential function with slope, X. Extrapolation of this slope to time zero permitted estimation of the background radioactivity which was used in calculation of VH. Seven patients were studied who had a history of hyperthyroid Graves' disease. Patient N.M. had received an 18 month course of treatment with propylthiouracil and was euthyroid at the same time of the study, 1 yr after the drug had been discontinued. All other patients had received radioiodine therapy from 6 months (J.P.) to 15 yr (J.V.) previously. Patients H.B. and W.B. were clinically hypothyroid; the other cases in this group were euthyroid. Two of the latter group, J.V. and M.H., were taking replacement therapy (L-thyroxine). J.P. was studied both before "'I therapy and after he was rendered euthyroid. The study included three euthyroid male subjects who exhibited a decrease in plasma TBG-binding capacity. One of these cases (M.G.) was a control subject who was restudied after a period of 4 wk on methyltestosterone, 100 mg a day. In the other two individuals, the decrease in TBG was on an idiopathic basis.
Total serum thyroxine iodine was measured chemically (10). The T4-binding capacity in serum TBG was estimated by paper electrophoresis in ammonium carbonate buffer as described previously (9) .
The proportion of free T4 in serum (free T4 fraction) was determined indirectly using a method of adsorption by Sephadex1 described elsewhere (11) . This technique provides an estimate of the change in free T4 fraction relative to a control reference serum; the results are expressed as a per cent of the control value.2
RESULTS
The kinetics data obtained in a typical infusion experiment are shown in Fig. 2. A constant 'I level in plasma was reached in all cases as early as 3 min after the administration of the priming dose (time zero) and remained unchanged throughout the period of the infusion. Radioactivity over the liver rose rapidly during the initial 20-40 min reaching a constant level which was maintained during the remainder of the study. The counting rate over the thigh rose more slowly than that over the liver and continued to increase during the period of the infusion.
Analysis of the hepatic curves, in four representative studies, is illustrated in Fig. 3 (Table I) .
Continuous monitoring of radioactivity over the thigh during the sustaining infusion of Ts-'I revealed a rapid rise in counting rate during the initial 3-6 min after injection of the priming dose. This phase presumably represents, for the most part, distribution of the tracer throughout the vascular spaces of the thigh. Subsequently in all subjects, radioactivity in the thigh rose more slowly and at nearly a constant rate for approximately 20-30 min, increasing somewhat more gradually during the remainder of the period of infusion. The relative change in thigh "uptake" was expressed as a per cent of the 10-min counting rate during the study, no correction was made for circulating label. Fig. 4 shows, for each of the groups of subjects, the average thigh ratios obtained. Fig. 4) .
In an effort to determine whether the fractional rate of transfer of Ts from plasma to liver is limited by the availability of free hormone in plasma, we compared the individual values for CH with those for free T4 fraction. As shown in Fig. 5 , a high degree of correlation was found among the subjects without Graves' disease (r = + 0.86; P < 0.01). In contrast, the patients with Graves' disease, both treated and untreated, showed values for CH which were higher than predicted from the free hormone fraction.
DISCUSSION
The results of the present study permit a comparison of Ts and T. in regard to distribution in man. The hepatic distribution volume (Vex) for Ts is about one-half that for T4, determined in our previous study in a different but comparable group of control subjects (9) . Given the nearly 10-fold greater binding activity by plasma proteins of To compared with T3 (12), the observed difference in VH between the two hormones implies that the liver binds To nearly 20 times more strongly than T3. The -difference between To and To can be stated also in terms of the proportion of total-body hormone which is in the liver after equilibration of tracer is complete. Using average values from the literature (13), the total Ta space in a 70 kg man is about 40 liters, nearly 3.5 times the T4 space. The liver contains at equilibrium approximately 30% of the total T4 outside of the thyroid gland (9) . In contrast, according to the results of the present study, only about 5% (2 liters/40 liters) of the total T8 pool is within the liver. Thus, the hepatic content of T3 is much less than that of T4 both in absolute terms and as a fraction of the total-body hormone.
These findings in man agree, in general, with the observations in several species of animals. Thus in the rat (14) , the dog (15) , and the rabbit (16) at early time intervals after injection of either labeled hormone, the liver takes up approximately 25% of the dose. In the case of T4, the liver retains a large fraction of the dose; most of the remainder is in extracellular fluid (15) . Hepatic content of labeled T3, on the other hand, in cells of extrahepatic tissues, for the most part, skeletal muscle (16) . In our control subjects the one-way clearance (CE) of TI, a measure of the fractional rate of transfer from plasma to liver, averaged 231 ml of plasma per min which is nearly 5 times greater than the corresponding value for T4 (9) . This finding of a difference between the two hormones in respect to hepatic clearance is consistent with the known difference in binding activity of plasma proteins and supports the thesis that the entry of the hormone into the liver is limited to the free hormone. Further evidence for this view is provided by the observations made in the present study of euthyroid individuals with decreased binding by plasma TBG. Among these subjects, the increase in CE above control levels was directly proportional to the decrease in overall binding of thyroid hormone by plasma proteins (Fig. 5 ).
In spite of the relatively low hepatic space for Ti, the one-way clearance by liver is slightly higher than the total unidirectional clearance by all other tissues combined. Assuming a linear rate of change in VCEH during the initial 20 min after the single injection of labeled Ts, the one-way clearance by extrahepatic tissues is approximately 160 ml/min (3.25 liters/20 min) in our control subjects. The liver, therefore, receives about one out of every two molecules of Ts that leave the circulation. It must be emphasized that this process is not net (metabolic) clearance. In man the total-body metabolic clearance rate of Ts is approximately 15 ml/min (13) , which is less than one-tenth the one-way hepatic clearance obtained in the control subjects of the present study. Therefore, more than nine-tenths of the Ts which enters the liver per unit time must return to the plasma in unaltered form.
Analysis of the distribution kinetics data for extrahepatic tissues presents a more complex problem than in the case of the liver. The increase in the apparent distribution volume in extrahepatic tissues, VIE, as a function of time after the single-injection of Ts-'I reflects several processes which probably occur simultaneously. These include diffusion of tracer out of the plasma, equilibration in the interstitial compartment, and penetration into cells. Interpretation of the kinetics data is complicated further by the likely possibility that extrahepatic tissues are heterogeneous with regard to the rate of equilibration. Studies in experimental animals have shown that organs differ markedly in the rate of uptake of labeled Ts after intravenous injection of the tracer (14) (15) (16) . In general, liver and kidney take up the label rapidly; most other tissues, including skeletal muscle, equilibrate slowly. The results of the present study demonstrate in man a similar difference between liver, and perhaps kidneys, on the one hand, and the thigh on the other, with respect to the rate of equilibration of labeled Ts.
The moderate degree of correlation (+ 0.66) between the values of the serum hormone fraction and those of VisE at 20 min after the single injection suggests that the level of free T3 in the circulation is an important determinant of the rate of diffusion of Ts into rapidly equilibrating extrahepatic tissues. The absence of a correlation between the free hormone fraction and increments in ViC during later intervals could be explained by postulating that the rate of diffusion of T3 into slowly equilibrating tissues is relatively insensitive to alterations in plasma binding activity. The data regarding the thigh accumulation during the infusion of labeled T3 are consistent with this formulation. In view of the complexity of the kinetics in extrahepatic tissues, the above interpretation is offered only as a tentative hypothesis.
The dichotomy with regard to the distribution kinetics of Ta between rapidly equilibrating sites (e.g., liver) and relatively slow equilibrating tissues (e.g., thigh) provides a possible explanation for the observations of Zaninovich, Farach, Ezrin, and Volpe (17) . They reported that the rate of disappearance of labeled Ta from the plasma during the interval from 20 to 50 min after rapid injection of the tracer into humans was not affected by alterations in the plasma TBG, even though such alterations are known to result in large changes in the proportion of free Ts in vitro. On the basis of their studies these workers suggested that Ta is not bound to any appreciable extent to TBG in vivo. The results of the present study, on the other hand, by demonstrating that the rate of entry of Ta into liver is a function of the binding activity of plasma TBG, point to a significant in vivo role for TBG. Since equilibration of tracer between plasma and liver is virtually completed within 20 min after a single injection of labeled Ta, the decrement in plasma content of label between 20 and 50 min, the period studied by Zaninovich et al., probably reflects distribution of Ts into extrahepatic tissues, a process which we postulate to be insensitive to alterations in plasma binding of the hormone. A similar explanation for the findings of Zaninovich et al. has recently been offered by Musa, Kumar, and Dowling (18) .
Recently Woeber, Hecker, and Ingbar (19) have obtained more direct evidence for in vivo binding of Ts by plasma proteins. After injection of a large loading dose of T4 into normal subjects, they observed a significant increase in the volume of distribution of a tracer dose of labeled Ta. The increment in the Ta space was evident within 20 min after administration of the tracer and persisted throughout the period of equilibration in the body. The authors concluded that the T. In a number of studies devoted to the late phase of T3 kinetics, after tracer equilibration is complete, a decrease in binding activity by TBG has been associated with a decreased fractional rate of T3 turnover (20) (21) (22) . These findings, being directly opposite to the alterations observed in the case of T4, have been offered as further evidence that TBG is of little or no significance in the transport of T3 in vivo (22) . An alternative interpretation, however, can be given. When binding activity of TBG is diminished, T4 is redistributed from extracellular to intracellular sites (23) particularly into the liver (9) . This shift in T4 occurs both in subjects with a primary decrease in TBG activity (9, 23) and in normal subjects given an acute loading dose of T4 (24) . An increase in hepatic T4 content under these circumstances might compete effectively with hepatic T3 for metabolic disposal even in the face of enhanced hepatic uptake of T3. The result would be a decrease in the fractional turnover (disposal) rate of T,. Thus, the apparently contradictory effects of diminished TBG binding activity on the fractional turnover rates of T4 and T3 can be explained on the basis of shifts in T4 distribution with the attendant effects on T3 metabolism. There is then no need to discard the idea that TBG binds both hormones in vivo.
The kinetics of T3 distribution among the subjects with Graves' disease, treated and untreated, appear to be altered in a manner not explicable simply on the basis of known shifts in binding equilibrium. Thus, the increases in CH observed in both the hyperthyroid and treated patients were out of proportion to the increase in the percentage of free hormone (Fig. 5) (26) .
Both in treated and untreated patients with Graves' disease the unidirectional hepatic clearance of T3 was elevated out of proportion to the circulating free hormone fraction. This suggests that an abnormality may exist in the liver itself in this disorder. One possibility is that the hepat c cell membrane is altered in such a way as to permit an increased rate of exchange of the hormone between the plasma and intracellular binding sites. Although there is no evidence for its existence, an active transport process governing the entry of thyroid hormones into the liver might explain these results. Such a process could be abnormally active in Graves' disease. Whatever explanation is invoked, the persistence of the abnormality for many years after treatment of hyperthyroidism must be taken into account.
Recent measurements of total T3 concentration in plasma indicate that abnormally high levels of this hormone may be found in some patients with this disease after their hyperthyroidism has been controlled (2) . Whether this phenomenon is related to the abnormal d's'ribution kinetics of Ts observed in the present study remains to be determined.
Nearly a decade ago, Hales and Dobyns (27) reported studies of T3 metabolism in Graves' disease. The disappearance of label from the plasma during the initial hours after a single injection of T--"JI was delayed and the radioactivity over the liver declined more abruptly in patients with Graves' disease, both in hyperthyroid and in treated cases, compared to normal controls. These authors suggested that the liver might play a special role in the peripheral distribution and metabolism of T3 in Graves' disease. Since they presented no data obtained during the initial 60 min after injection of the labeled T3 and since their subjects received propylthiouracil during the study, it (29) , who noted an increase in the fractional turnover rate of T4 in some patients long after successful treatment of their hyperthyroid-sm associated with diffuse toxic goiter. The weight of evidence, including the present observations with regard to the kinetics of T3 distribution, supports the view that an abnormality in the peripheral distribution and metabolism of thyro'd hormones is a feature of Graves' disease.
APPENDIX
The method employed for estimating the hepatic distribution volume, VH, rests on two important assumptions. First, it is assumed that the phantom used for calibration of the hepatic detector closely simulates in vivo conditions. The scintiscans made at the end of the infusion of T3-'I showed a uniform distribution of 131I within the liver; the hepatic image in every case corresponded reasonably well to the size and shape of the phantom.
The second major assumption concerns the correction for "background," defined as the radioactivity in vascular spaces and in extrahepatic tissue within "view" of the hepatic detector. In the calculation of VH it is assumed that the background (Lo) remains constant during the period of hepatic equilibration, i.e., the initial 30-40 min of the infusion. This assumption is supported by the observed constancy in counting rate over the liver after hepatic equilibration is achieved (Figs. 2 and 3) and by the constant level of tracer in the plasma during the entire period of the infusion. In order to test the accuracy of the background correction, quantitative scintiscans were done in five of the subjects of this study. The scanning method was virtually identical tothat employed by Nicoloff and Dowling for estimating hepatic T4 content in man (28) , except that the scans were made at the end of the infusion of T3-'1I. The plastic phantom of the liver was used as a standard. Estimates of VH by the quantitative scanning method ranged from -15 to +12%o of the values obtained by the fixed detector method (average difference = -3%). Thus, the reasonably good agreement between the two methods of estimating VH for T3 tends to support the validity of the second assumption.
The following additional assumptions underlie the method of estimating VH and CH: metabolic transformation of labeled Ts during the 2-hr period of infusion is negligible. A steady state exists during the same interval, i.e., the rate of entry of unlabeled Ts into the liver equals the rate of loss from the liver by all routes. The concentration of labeled T, in the plasma of the antecubital veins (site of sampling) is the same as that in the plasma entering the liver, the level of tracer in both sites being constant during the sustaining infusion. Finally, single-compartment kinetics are assumed for hepatic T,. This latter assumption appears justified in view of the single-exponential character of the hepatic accumulation curve in all subjects.
In a recent study of thyroid hormone distribution in man, Musa et al. (18) , using a single injection of labeled T, and a method of external monitoring similar to ours, estimated hepatic Ts distribution volume, uncorrected for background, in five normal subjects. They obtained a mean value of 3.6 liters ±0.97 sD. Applying our average correction for background (Lo/Lmax) to their data yields a value for VH of 2.2 liters. This result agrees well with the mean VH of 2.07 liters for the control subjects.
Until more direct measurements of hepatic Ts distribution volume and unidirectional clearance rate are made, the absolute values obtained in this study must be regarded as tentative. Nevertheless, the conclusions based on comparisons among the different groups of subjects would appear to be valid.
